Latest Lead News

CLINUVEL Pharmaceuticals announces the full-time return of Managing Director Dr Philippe Wolgen, focusing on advancing critical product development and corporate initiatives, while Acting CEO Lachlan Hay continues until September 2025.

Brazilian Critical Minerals has achieved a significant milestone in its Ema project by successfully demonstrating magnesium sulphate migration and pH reduction in field trials, validating its in-situ recovery method for rare earth elements.

Viridis Mining and Minerals has been selected for a major Brazilian government funding package to accelerate its Colossus rare earth elements project, marking a pivotal step in diversifying global critical mineral supply chains.

AdAlta Limited has successfully placed the remaining shortfall in its renounceable rights issue, raising a total of $1.3 million to advance its cellular immunotherapy pipeline. The company also addressed an administrative breach involving director share allocations, ensuring compliance with ASX rules.

Syntara Limited is set to reveal fresh interim results from its Phase 2 trial of SNT-5505, targeting myelofibrosis, during an investor webinar ahead of a major European hematology conference.

Miramar Resources has partnered with Topdrill in a drill-for-equity agreement to fund significant drilling at the promising 8 Mile gold target within its Gidji JV Project near Kalgoorlie. Drilling is set to begin in July, aiming to explore extensions of a known gold deposit.

Accent Group reports a modest decline in like-for-like sales and margin compression in the second half of FY25, setting full-year EBIT guidance between $108 million and $111 million.

Challenger Limited has welcomed APRA’s consultation on new capital settings for annuity products, highlighting the potential for regulatory reforms to boost innovation and growth in Australia’s retirement income sector.

Hazel Group Limited has temporarily paused trading of its securities on the ASX, signaling an impending announcement that investors will want to watch closely.

HITIQ has partnered exclusively with Shock Doctor to launch the PROTEQT instrumented mouthguard, aiming to transform concussion management worldwide. The company also initiates a $2.92 million rights issue to fuel this ambitious rollout.

EVE Health Group has completed its acquisition of Nextract Pty Ltd, positioning itself to enter the lucrative erectile dysfunction and dysmenorrhea markets with innovative drug delivery technologies.

JPMorgan Asset Management has announced the June 2025 distribution and provided detailed tax attribution estimates for its US 100Q Equity Premium Income Active ETF, highlighting key income components and withholding tax implications.